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Introduction
The widespread use and over-use of antimicrobial drugs over the past 30 years has given rise to emerging resistance and poses a severe limitation to the application of antibiotics with bacterial pathogens.
1 Multi-drug resistant and extensively multi-drug resistant tuberculosis (TB) is now present in many countries. Mycobacterium tuberculosis, the microbe responsible for TB, has developed a reduced susceptibility to clinically used drugs, all of which were introduced 30-40 years ago. 2, 3 A similar situation is arising with fungal pathogens, such as
Candida albicans and Cryptococcus neoformans, which can cause debilitating oral and genital infections, but also lead to systemic infections with high mortality, especially in immuno-compromised patients including patients suffering from AIDS or undergoing chemotherapy or organ transplantation. [4] [5] [6] Anti-infective drug resistance presents a serious and immediate medical threat that requires urgent development of new drugs that ideally possess a novel mechanism of action. CAs (EC . CAs constitute an excellent example of convergent evolution, 8 and in addition to α-CAs from mammals there are four distinct, unrelated gene families (β-, γ-, δ-and ζ-CA families) that encode these metalloenzymes in organisms across the phylogenetic tree. 7, 8 Mammals possess only α-CAs, a completely unprecedented binding mode, with no interactions between the inhibitor molecule and the active site Zn 2+ observed. 17 In another contribution, Parkkila and colleagues 18 showed that imatinib and nilotinib (clinically used protein tyrosine kinase inhibitors with potent antitumor activity) were low nanomolar inhibitors of α-CA I and II, Figure 1 . The striking feature of these inhibitors is they lack the zinc binding sulfonamide group of classical CA inhibitors. There is precedence for a non-classical ligand binding mode to mammalian CAs as reported by Christianson and colleagues. 19 The crystal structure of human CA II in complex with the inhibitor phenol revealed this inhibitor bound in the active site cleft mainly because of van der Waals contacts with side chain residues of the hydrophobic side of the active site. The hydroxyl group of the inhibitor was found to interact with a zinc-bound water molecule through hydrogen bonding. Intriguingly, there was no direct interaction between the inhibitor and the zinc ion. 
CIN
Based on these observations it appears that new chemotypes possess the potential to provide novel CA inhibitors with drug-like properties. In this study, we thus employed a library of NP-based phenols to elucidate the structure-activity relationship of the phenol skeleton for inhibition of CAs from pathogenic organisms as well as human CA I and II. The pathogen elevated CO 2 levels, this fungus produces a polysaccharide capsule which has been identified as a major virulence factor for this pathogen. 28 This current study provides further grounding for the discovery of much needed novel small molecule probes to investigate the possible management of these infections through a new mechanism of action.
Results and Discussion

Compound library
As part of the ongoing collaborative research effort towards the discovery of novel NP inhibitors of CAs 17,29 a library of phenolic NPs (1-13, Figure 2 ) and synthetic phenols based on a NP scaffold (14-21, Figure 3 ) was assembled and considered for M. tuberculosis, C.
albicans and C. neoformans β-CA and human CA I and II inhibitory investigations. Although diverse in structure, the library compounds share a common structural feature comprising at least one phenolic fragment. Compounds were chosen from a unique NP-based library.
Phenols that were isolated or synthesised in quantities greater than 1 milligram were used in the current studies. The majority of these 23 compounds used in this work are from a variety of structure classes that cannot be readily accessed by other means. The NP library consisted of eight fungal (1-6a, 9-10), two ascidian (7, 8) and three plant (11-13) secondary metabolites.
Specifically, the NPs were a series of simple mono-or disubstituted phenols 1-5, [30] [31] [32] 
Carbonic Anhydrase Inhibition
The inhibitory activity of the compounds shown in Figures 2-4 Table 1 . This inhibition data was acquired using a stopped flow assay that monitors the physiological reaction, that is, the CA catalyzed hydration of CO 2 . 
M. tuberculosis β-CA inhibition: Rv1284
The Rv1284 CA was inhibited very weakly by phenol (K i of 64 μM), the core fragment scaffold of the NP library, while all compounds from the NP library exhibited enhanced enzyme inhibitory activity for this isozyme compared to phenol. As for β-CA Rv3273, Compounds 7 and 8 differ by one CH 2 group and have a 13-fold difference of inhibitory activity. Compounds 9 and 10 differ by the presence of a -CH 2 OH moiety in 10 compared to a -CH 3 moiety in 9, here the difference of Rv1284 inhibitory activity is ~11-fold. Thus small and simple structural changes have the capacity to impart significant effects of Rv1284 CA inhibitory activity.
C. albicans and C. neoformans β-CA inhibition
Phenol was a weak C. albicans Nce103 CA inhibitor, with a K i of 17. Human CA II was generally better inhibited by 1-21 than human CA I, yet activity remained in the low micromolar range for many compounds, again similar to that of phenol (K i of 5.5 μM). NPs 5 and 13, whilst better human CA II than human CA I inhibitors, showed very weak human CA II inhibitory activity (K i s of 131 and 230 μM, respectively) compared to the remainder of the NP-based library. It is significant to note that minimal structural changes can lead to significant differences of CA inhibitory properties. For example, the carboxylic acid 4, while structurally related to amide 5, was a much stronger human CA II inhibitor than 5 (15-fold). Also of note is that the more flexible lignan, (-)-dihydroguaiaretic acid 13, showed 19-fold weaker human CA II inhibitory activity compared to the more rigid cyclobutane lignans, endiandrins A 11 and B 12, indicating a potential avenue for further SAR exploration. As for human CA I, the most active NP human CA II inhibitor was the sulfonamide 18 with a K i of 18 nM, this compound has inhibition comparable to the clinically used drugs AZA and TPM (K i s of 10 and 12 nM, respectively). Compound 18 has been shown earlier by one of our groups to also act as an efficient inhibitor of the bovine enzyme ortholog to human CA II. 43 
CA inhibition selectivity profiles
Selectivity for β-CAs against α-CAs is an important consideration for downstream use of these compounds as chemical probes, for example in vivo studies to evaluate the druggability of the pathogen enzymes. The selectivity ratios of β-CA inhibition versus α-CA I and α-CA II inhibition are presented in Tables 2 and 3 , respectively. The clinically used CA inhibitors SA, AZA, TPM and ZNS as well as phenol were less effective inhibitors for the mycobacterial and fungal β-CA enzymes. The reverse trend was observed for many of the phenolic NPs derivatives reported here, with many exhibiting a marked selectivity for the inhibition of the β-class CAs over the α-CAs, Table 2 and 3. The selectivity ratios listed in Table 2 show that NP-based phenols 1-13 and 19 were up to several hundred-fold selective for pathogen CAs over human CA I and thus may represent leads for better discriminating the inhibition of β-CAs from pathogens. Clearly, the synthetic NP based phenols 14-18, 20 and 21 were less effective in this respect, since they showed a maximum of The situation is very different for the α-CAs, where phenolic compounds were generally 1-2 orders of magnitude less efficient α-CA inhibitors than classical sulfonamide or sulfamate inhibitors. [44] [45] [46] [47] The consistency of this observation across four distinct β-CAs provides a compelling opportunity to explore the phenol scaffold in the development of potent and selective inhibitors for the β-family of CAs.
Structural analysis of ligand-protein interactions
Previously, two structural entities not directly interacting with the active site zinc ion have been reported as inhibitors for α-CAs, phenol 19 and coumarins. 17, 48 Intriguingly, the crystal structure of ligand-bound human CA II using the naturally occurring coumarin derivative 6- 19 Surprisingly, the crystal structure revealed that it is the methyl ester distal to the phenol moiety of 6b that sits in the inner part of the active site cleft. The ester carbonyl of 6b interacts with a zinc-bound water molecule and is further engaged in a hydrogen bond donated by the backbone amide group of Thr198. In this crystal structure, the electron density of the inhibitor is well defined, allowing unambiguous placement of the ligand. This is a totally new binding mode to CAs. Furthermore, the binding is similar to that of the polyamines, a recently described new chemotype for the CA inhibition.
anchors to the zinc-coordinated water (hydroxide ion) from the CA active site through one of its primary amine moieties exactly as the methyl ester from 6b reported here does. Thus, we now provide evidence through a third example (after phenol and spermine) that anchoring to the non-protein zinc ligand in the CA active site may be a valid mechanism to inhibit carbonic anhydrases in the low micromolar range. The binding of compound 6b to the active site is further supported by a number of hydrogen bonds and van der Waals interactions with active site residues and solvent molecules. The electron density clearly indicated two alternate conformations for the phenol moiety of 6b (rotation of 180° around the vertical phenol axis), thus giving rise to the chloro substituent appearing on both sides of the phenolic hydroxyl group. We have attempted to crystallize Can2, Nce103, Rv3273 and Rv1284 enzymes in the presence of various inhibitors, including the NP-based phenols, so far without success. A caveat exists when using human CA II as a prototype for structural investigation of the mycobacterial and fungal CAs. While the enzymes belonging to the α-and β-class of CAs have in common the existence of an active site zinc ion, there are considerable structural differences. Firstly, all known β-CAs exist as dimers, whereas α-CAs are monomeric enzymes, except CA IX which is a dimer. 51 The catalytically important residues in the active site of β-CAs are provided exclusively from one monomer, but access to the catalytic centre may be constituted by residues from both monomers, i.e. assessment of the active site cleft requires analysis of the functional dimer, Figure 7 . No structural information is available for
Rv3273, but the crystal structure of Rv1284 has been reported. 22 Importantly, the active site 
Conclusions
We have investigated the enzyme inhibition characteristics of a phenolic-based NP library This study provides the compelling indication of the usefulness of novel chemotypes such as phenols, especially for targetting both α− and β-CAs. We anticipate that this study will provide a valuable platform to guide the development of future CA inhibitors comprising novel chemotypes with improved activity and drug-like properties for targetting pathogen CA enzymes. Such compounds may be useful for the development of chemical probes and the design of antifungal and antimycobacterial agents, representing a new scientific opportunity with a novel mechanism of action towards treating infections for which multidrug resistance is a current major health concern.
Experimental
Chemistry
The isolation of NPs 1-13 has been described earlier. 30, [33] [34] [35] [36] [37] [38] 43 The synthesis of NP analogues 14-21 was achieved by the reaction of 3-chloro-4-hydroxyphenylacetic acid (4) with a panel of eight different primary amines using 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide hydrochloride and 4-dimethylaminopyridine in CH 3 CN at room temperature as described earlier. 39 All compounds were analyzed for purity by C 18 μPLC and shown to be >95%. This microfluidic purity analysis methodology has been previously reported. 55 (+)-Xylariamide A
